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Blood platelets are involved in a number of immune reactions and, by release 
of vasoactive amines and thromboplastic factor(s), may contribute to vascular 
injury and  deposition  of fibrin  (1,  2).  Platelet  injury  can be induced  by bac- 
terial  endotoxins  (3,  4)  and  immune  complexes  (5-7),  both  of which  require 
complement, and by membrane-active bacterial toxins such as streptolysins O 
and S and staphylococcal alpha toxin, which act directly on the platelet mem- 
brane without  the participation  of complement  (8). 
Staphylococcal protein A  (SPA)] a component of the cell wall of coagulase- 
positive staphylococci, is known to elicit a number of immune reactions such as 
Arthus-like reaction in rabbits and immediate skin hypersensitivity in humans 
(9,  10).  SPA is unique  among microbial products in  that it inteiacts with the 
Fc portion  of immunoglobulin  G  (IgG) rather  than  with  the  antigen-binding 
site  on  the  Fab  portion  of  the  immunoglobulin molecule  (11,  12),  and  fixes 
complement presumably as a  result of this interaction  (13).  Since some of the 
immune reactions elicited by SPA,  such as the Arthus reaction in rabbits,  are 
thought  to  involve leukocytes  and  platelets  (14),  it  seemed  pertinent  to  in- 
vestigate the  interaction  of SPA  and  rabbit platelets in  vitro.  The results of 
these studies indicate that  (a)  SPA does induce rabbit platelet injury,  (b) that 
the reaction requires complement, and (c) that a sharp concentration optimum 
exists, larger amounts of SPA being inhibitory. 
Further,  evidence was obtained  that  SPA-induced  platelet  injury  could  be 
separated into  two  steps; first,  "sensitization,"  an  interaction  of SPA with  a 
noncomplement plasma factor and platelets,  and  second,  amine "release" due 
to complement-dependent platelet injury. 
* Supported by research grants from the Veterans Administration and by grants AI-03082 
and AI-00323 from the US Public Health Service National Institutes  of Health. 
1  Abbreviations used in this paper: CoF, cobra venom factor; EDTA, disodium ethylene- 
diaminetetraacetate;  5HT,  5-hydroxytryptamine; IgG,  immunoglobulin G, PPP,  platelet- 
poor plasma; PRP, platelet-rich plasma; SPA, staphylococcal protein A. 
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Materials and Methods 
Staphylococcal Protein A .--Crude  SPA from a  culture of Staphylococcus aureu* Cowan  1 
(kindly  provided  by  Dr.  Jay  Cohen,  Communicable  Diseases  Center,  Atlanta,  Ga.)  was 
prepared  by Jensen's heat-extraction method as  described by  Forsgren and SjSquist  (15). 
Further purification of lyophilized crude SPA was  performed by ion-exchange chromatog- 
raphy on a  diethylaminoethyl (DEAE)-Sephadex column  (Pharmacia Fine Chemicals, Inc., 
Piscataway,  N.  J.)  (2.5  >( 45  cm)  equilibrated  with  0.05  ~  tris(hydroxymethyl)amino- 
methane-HC1 buffer, pH 8.0.  100 mg of SPA protein dissolved in the initial buffer was applied 
to the column. The chromatogram was developed with an NaC1  concentration gradient  as 
illustrated in Fig.  1. Fractions were collected and analyzed for SPA activity, and those con- 
taining active material were pooled and concentrated by pressure dialysis using an Amicon 
UM  10 membrane filter (Amicon Corp., Lexington, Mass.).  In some experiments the active 
material was rechromatographed under the same conditions as  in  the initial column sepa- 
ration. 
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FIG.  1.  Separation of SPA on DEAE-Sephadex column. Distribution of protein and SPA 
activity precipitating IgG (hatched bar). 
Determination of SPA Actlvity.--Fractions were analyzed for SPA activity using the quan- 
titative single immunodiffusion method of Mancini et al.  (16)  as modified by Forsgren (17). 
Fig.  2  (upper panel) demonstrates the precipitation rings caused  by increasing concentra- 
tions of SPA in agar containing a  standardized concentration of pooled human gamma glob- 
ulin (Pentex Biochemical, Kankakee, Ill.). The precipitates were developed by staining with 
Buffalo black.  The lower panel  in  Fig.  2  demonstrates the  same assay  in agar  containing 
rabbit gamma globulin (Pentex Biochemical). Although the concentrations of the two species 
of gamma  globulins used were similar, the diameters of the zones of precipitation and the 
intensity of  staining of  the  precipitation bands was  much greater with human than with 
rabbit gamma  globulin.  Tube  precipitation of  rabbit gamma globulins with SPA was  per- 
formed following the method of Kronvall and Gewurz (18). 
Disc Electrophoresis in Polyacrylamide Gel followed by Immunodid~usion.--Both  crude SPA 
and  chromatographically  purified  active  material  were  analyzed  by  disc  electrophoresis 
carried out by the method of Davis (19)  employing a  polyacrylamide concentration of 7.5% 
in the separation gel at pH 8.9. After electrophoresis, the gel cylinders were cut longitudinally 
one-half was stained for protein with Coomassie blue, and the unstained half was placed on a 
microscope  slide  and  layered  with  1.5%  Nobel agar  dissolved  in  Veronal buffer,  pH  8.6. 70  COMPLEMENT-DEPENDENT  PLATELET  INJURY  BY  PROTEIN  A 
After  solidification of  the agar  surrounding  the  partially  immersed  half  cylinder  of  poly- 
acrylamide, a  longitudinal trough cut lateral to  the gel was filled  with 0.1%  pooled human 
gamma  globulin  (Pentex Biochemical).  The  preparation  was  incubated for  48  hr at room 
temperature to allow diffusion of protein from the gel and precipitation of diffusing material 
FIG. 2.  Precipitation of IgG by SPA as measured by quantitative single immunodiffusion 
in agar. (Upper panel): agar contains pooled human gamma globulin in concentration 1 mg/1 
ml of agar.  Concentration of SPA applied  to  the agar:  1,  10, 50,  100, 250, 500,  1000,  1500, 
and 3000/zg starting with upper left well.  (Lower  panel): agar contains pooled rabbit gamma 
globulins.  Agar  was  stained  with  Buffalo  black. 
FIG.  3.  Disc electrophoresis and "disc immunodiffusion" patterns of SPA.  Stained poly- 
acrylamide gel  opposed  to  the agar at  the position which  was  originally occupied  by un- 
stained polyacrylamide gel containing SPA. 
with human gamma globulin. After incubation, the half cylinder of polyacrylamide gel was 
gently removed with forceps, and the slide was immersed in saline for 24 hr, distilled water 
for 48 hr, dried under strips of filter paper at 37°C  for 24 hr, and finally stained with Buffalo 
black. Fig. 3 demonstrates the precipitates which developed between protein (SPA) diffusing 
from  the  polyacrylamide  gel  and  human gamma  globulin diffusing from  the  trough.  The 
half cylinder of polyacrylanfide which was stained for protein has been placed in the exact 
position of the unstained half cylinder from which diffusion took place. This combined method HAWIGER~  MARNEY~ COLLEY, AND  DES  PREZ  71 
of disc electrophoresis and double immunodiffusion in agar gel made it possible to identify 
with certainty the bands  in polyacrylamide  gel  which contained  SPA  activity as  demon- 
strated by precipitation with normal human gamma globulin. The active fraction of crude 
SPA demonstrated the same electrophoretic mobility in polyacrylamide as did the material 
purified by DEAE-Sephadex chromatography. 
Other Methods.--Protein concentration was  determined  by  the  method  of Lowry  et al. 
(20).  The absence of mucopeptide or teichoic acid in crude or purified SPA preparations was 
demonstrated by a  negative reaction for N-acetylamino sugars after acid hydrolysis accord- 
ing  to  the  method  of  Reissig  et  al.  (21).  Staphylocoagulase activity was  assessed  by  the 
method of Tager and Hales  (22)  and staphylococcal alpha toxin activity by the method of 
Duthie  (23).  Neither  activity  was  detectable  in  crude  SPA  nor  the  chromatographically 
purified fraction. 
Demonstration of Platelet Injury.--Release  of  platelet  5-hydroxytryptamine  (5HT)  into 
plasma was utilized as the index of platelet injury. Rabbit platelet-rich plasma  (PRP)  was 
prepared by differential centrifugation  (900  rpm for  10  rain)  of blood anticoagulated with 
disodium  ethylenediaminetetraacetate  (EDTA)  (Mallinckrodt  Chemical Works,  St.  Louis, 
Mo.)  and  heparin  (Connaught  Medical  Research  Laboratories,  Westlake,  Ontario)  (final 
concentrations of 0.1% and 40/zg/ml plasma, respectively). The supernatant PRP was re- 
moved by aspiration and the EDTA then neutralized by addition of an equimolar concen- 
tration of calcium chloride. The details of PRP  preparation have been previously reported 
(24).  Aliquots  of  heparinized  PRP  were  challenged  with  the  indicated  concentrations  of 
SPA added in a volume of 0.1 ml/ml PRP and incubated at 37°C while undergoing slow rota- 
tion on an inclined disk. The reaction was terminated by addition of 10 m~ EDTA after which 
the platelets were sedimented by high speed centrifugation at 4°C, the concentration of 5HT 
in  the supernatant platelet-poor plasma  (PPP)  was  determined photofluorometrically, and 
results were expressed as per cent of total platelet-5HT available for release. 
Two-Step Experiments.--As indicated under Results,  a  series of experiments was under- 
taken to determine if SPA caused any change in platelets under conditions in which comple- 
ment  was  inhibited.  Basically,  this  was  accomplished  by  exposing  EDTA-PRP  to  SPA. 
After  appropriate  incubation  (step  one)  the  mixture  was  spun  down,  plasma  containing 
"unbound" SPA was discarded, and platelets were washed three times in a modified Tyrode's 
solution according to the procedure of Ardlie et al.  (25),  modified by the use of EDTA rather 
than ethylene glycol tetraacetic acid in a  final concentration of 5 m~.  Subsequently, plate- 
lets were resuspended in fresh, heparinized plasma containing no EDTA and no SPA.  After 
this reincubation  (step  two),  the amount  of  5HT  released from platelets was  determined. 
EDTA-PRP used in step one and heparinized plasma used in step two could be modified in a 
number of ways  (see Results). 
Complement Assay.--Hemolytic  complement activity was  determined by a  modification 
of Yachnin's method using various dilutions of recalcified plasma in Veronal-buffered saline 
containing optimal concentrations of  Ca,  Mg,  and gelatin  (26).  0.5  ml of sensitized sheep 
red blood cells  (5 x  10S/ml)  was added  to 2  ml of diluted plasma and the mixture was in- 
cubated at 37°C. After 60 min of incubation, 5 ml of saline was added, the unlysed erythro- 
cytes were sedimented, and  the optical density of  the supernatant was  determined at 540 
m/~. The results were expressed as per cent of hemolysis obtained in a  control sample after 
lysis of the erythrocytes by freezing and thawing. 
Cobra Factor.--Cobra factor  (CoF) was isolated from lyophilized Naja naja cobra venom 
(Ross Allen Reptile Institute,  Silver Springs,  Fla.)  by chromatography on DEAE-cellulose 
(27). 
RESULTS 
Release  of 5HT from Platelets  by SPA. Requirement for Plasma Factor(s).-- 
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5HT. No release of 5HT was observed when washed platelets resuspended in 
buffer  were  exposed  to  SPA.  Further,  washed  platelets  exposed  to  SPA  in 
buffer, rewashed,  and resuspended in heparinized plasma did not release 5HT. 
These and similar experiments indicated that SPA did not alter platelets in the 
absence of plasma. The results are summarized in Table I. 
TABLE  I 
Dependence of SPA-Induced Rdease o[ 5HT from Platelets upon Plasma-SPA Interaction 
Reaction mixture  Per cent of 5HT released 
Platelets +  plasma +  SPA* 
Platelets +  Tyrode's +  SPA* 
SPA-pretreated platelets +  plasma:~ 
Saline-pretreated platelets  +  plasma~ 
% 
58 
3 
3 
9 
* Platelets were washed three times in Tyrode's solution containing EDTA (see Materials 
and Methods)  and resuspended in recalcified PPP or in Tyrode's solution containing no 
EDTA. SPA was added in final concentration of 100 pg/ml and system was incubated  for 
30 min at 37°C. 
:~ SPA (100/zg/ml) or a control amount of saline was added to washed platelets in Tyrode's 
and incubated for 30 min at 37°C. Platelets were then sedimented, washed twice in EDTA- 
Tyrode's,  and resuspended in heparinized PPP.  This  mixture  of pretreated  platelets  and 
plasma was then incubated for 30 min at 37°C. 
TABLE  II 
SPA-Plalelel Interactiou in Plasma with Inactivated Complement System 
Reaction mixture  Per cent of 5HT released 
% 
SPA +  platelets +  heated plasma*  0 
SPA -I- platelets +  EDTA-plasma~C  2 
SPA +  platelets -I- CoF-treated plasma§  1 
SPA +  platelets +  untreated plasma  32 
* Plasma heated  to 56°C for 30 min and centrifuged to remove precipitated  fibrinogen 
before resuspension of platelets and challenge with SPA (100 #g/ml final concentration). 
:~ Plasma containing EDTA in a final concentration of 10 m.u. 
§ Plasma  treated  with cobra factor in concentration 172.5/zg/ml  before resuspension of 
platelets and SPA challenge. 
Complement  Dependence  of  SPA-Induced  5HT  Release.--Since  release  of 
platelet 5HT by SPA required plasma and since SPA is known to fix comple- 
ment  (13),  it  was  necessary to  determine whether  complement was  required 
for  SPA-induced platelet  injury. As  illustrated in Table II,  prior decomple- 
mentation of plasma by heat or by treatment with cobra factor prevented SPA- 
induced 5HT release, and the presence of EDTA in a  concentration exceeding 
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Concentration Effect of SPA on Serotonin  Rdease, Complement Consumption, 
and Precipitation of IgG.--The  complement dependence of this phenomenon 
was  further supported  by  experiments in  which  the  hemolytic complement 
activity remaining in plasma was determined after SPA-induced 5HT release. 
Fig. 4 shows that release of 5HT was parallel to the consumption of comple- 
ment and that both 5HT release and complement consumption were maximal 
within a narrow range of SPA concentration (50-100 #g), higher concentrations 
being inhibitory. In contrast, precipitation of IgG by SPA was  directly pro- 
portional to SPA concentration throughout a wide concentration range. 5HT 
release and complement fixation by SPA therefore appear to be closely related 
phenomena. 
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FIC. 4. Effect of SPA concentration on serotonin release, complement fixation, and pre- 
cipitation of rabbit gamma globulin. 
Two-Step  Interaction  between SPA,  Plasma  Factor(s),  and  Platelets.--The 
data presented above indicated that one plasma factor required for interaction 
of  SPA  and  platelets  was  complement.  Since  complement fixation by  SPA 
requires an interaction of SPA with IgG (13), it was logical to postulate that 
Ielease of platelet 5HT by SPA also involved an initial SPA-IgG interaction. 
Indirect evidence compatible with this concept was obtained in the two-step 
experiments outlined  schematically in  Fig.  5  and  described under Materials 
and Methods. 
The essential finding of this type of experiment was that platelets exposed 
to SPA in EDTA-plasma (in which complement is inhibited and 5HT release 
is not observed) became "sensitized" or altered in such a manner that they did 
release 5HT when washed and then exposed to nonchelated plasma containing 
no SPA. As indicated earlier (Table I), similar experiments utilizing exposure 
of platelets to SPA in Tyrode's solution rather than in EDTA-plasma did not 
result in this type of sensitization to the action of complement. This was taken 74  COMPLEMENT-DEPENDENT  PLATELET  INJURY  BY  PROTEIN  A 
as evidence that a plasma factor other than complement was involved in the 
initial  SPA-plasma-platelet interaction. 
This experimental design made it possible to distinguish conditions affecting 
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FIG. 6. Effect of temperature on two-step interaction between SPA, plasma, and platelets. 
Closed bars: SPA added to the system; open bars: SPA not added (control). 
the  interaction  of SPA,  noncomplement plasma factor(s),  and  platelets  (sen- 
sitization  step)  from  conditions  affecting  release  of  5HT  (release  step).  As 
illustrated in Fig. 6, sensitization of platelets by SPA in EDTA-plasma was not 
inhibited at 4°C, whereas release of 5HT from sensitized platelets did not occur 
at low temperature. Fig. 7 demonstrates that the sensitization phase occurred 
without  an  appreciable  lag  period  whereas  release  of  5HT  from  sensitized SAWIGER~  MARNEY~ COLLEY, AND  DES  PREZ  75 
platelets was characterized by an initial lag period and progression over a 30 
rain period.  Finally,  decomplementation of plasma  used  in  the  sensitization 
step  was  not  inhibitory whereas  decomplementation of plasma  used  in  the 
release step completely eliminated 5HT release (Fig. 8). 
50- 
2 
o9 
5 
cL  0 
Fi RST  STEP 
~  50- 
I-- 
I"- 
o,  o 
o  5  ,;  ,~  2b  2;  30 
SECOND  STEP 
0  5  I0  15  20  25  50 
TIME  OF  INCUBATION 
FIG. 7. Effect of time on two-step interaction between SPA, plasma, and platelets. Closed 
circles: SPA added to the system; open circles:  SPA not added (control). 
w 
FIRST  STEP  SECOND  STEP 
50" 
i o,II 
COF  56°C  Control  C~F 56=~C  Control  30 rain  NO  (T  ........  )  .....  (Tr  eNtOmen  t  ) 
TREATMENT OF  PLASMA 
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DISCUSSION 
Platelet injury by staphylococcal protein A  (SPA), as described herein, is a 
new example of cell injury by a microbial product which is not due to a direct 
toxic effect but rather is mediated by the complement system. It resembles in 
many ways platelet injury by soluble immune complexes, which also  involves 
activation of complement, but is  clearly different in that it does not depend 
on a classic antigen-antibody reaction. 
The present  experiments are  submitted  as  evidence that  the  SPA-platelet 
interaction requires  both  complement  and  a  noncomplement plasma  factor. 
Tables I and II demonstrate that complement is necessary. Since SPA is known 
to cause complement fixation as a result of interaction with the Fc portion of 
IgG (13), and since 5HT release and complement fixation occur over the same 76  COMPLEMENT-DEPENDENT  PLATELET  INJURY  BY  PROTEIN  A 
narrow range of SPA concentration (Fig. 4), it seemed reasonable to postulate 
that IgG was also involved in SPA-induced platelet injury. Demonstration of a 
requirement for a noncomplement plasma factor (such as IgG)  could not be 
accomplished in single-step experiments using the complement-dependent end- 
point of 5HT release.  However, the two-step experiments illustrated in Figs. 
5-8  indicated that platelets could be sensitized by SPA under circumstances 
in which complement activity was prevented. Platelets sensitized in this fashion 
then proceeded to release 5HT when exposed to plasma containing an intact 
complement system. It  should be  emphasized  that  plasma was  required  for 
sensitization even though complement was not; many experiments of the type 
illustrated in Table I  indicated that platelets could not be sensitized by SPA 
unless plasma was  also  present.  The identity of the noncomplement plasma 
factor required for sensitization has not been  established to be IgG in these 
experiments,  although  as  mentioned  above  there  is  considerable  reason  for 
believing that this is probably the case. 
It is our present hypothesis that the SPA-IgG interaction exposes or activates 
IgG Fc determinants which then interact with receptors on the platelet mem- 
brane  leading  to  attachment  of  the  complex  and  subsequent  complement 
fixation. Such a mechanism has been suggested to play a role in platelet injury 
by soluble immune complexes (28). Attempts to establish attachment of SPA- 
IgG  complexes  to  the platelets using radiolabeled  IgG have to  date yielded 
inconsistent results. One possible explanation for this inconsistency has to do 
with the critical concentration optimum of SPA demonstrated for both com- 
plement fixation and platelet injury (Fig. 4). The concentration of SPA induc- 
ing maximal platelet injury was very close to the dose of SPA causing maximal 
consumption of complement but was 10 times lower than that giving maximal 
precipitation of IgG. This implies that full saturation of the IgG molecule with 
SPA (such as results in maximum SPA-IgG precipitation) will result in a loss 
of the  ability of IgG to interact with platelets and to  activate complement. 
Such  an  interpretation  is  concordant  with  observations  by  Kronvall  and 
Gewurz that saturation of the Fc fragment with excess SPA prevented fixation 
of complement by aggregated human IgG (18). In terms of molecular weight, 
SPA is a relatively small molecule (mol wt 15000) (15) in comparison with the 
Fc  fragment of rabbit  IgG  (tool  wt 55000)  (29),  and its binding to  the  Fc 
fragment does not block the complement-fixing site and presumably also does 
not block the postulated Fc site reactive with platelet membrane receptors. It 
is possible that the inhibitory effect of higher concentrations of SPA may be due 
to  polymerization of  SPA  on  the  Fc  fragment  of  the  IgG  molecule. High- 
molecular weight polymers of SPA could block Fc sites reactive with platelet 
receptors on the one hand and the first component of complement on the other. 
Such polymers of SPA might be formed by an excess of SPA added to plasma 
containing platelets. This possibility is supported by the isolation of a dimeric 
form of SPA  from SPA-IgG precipitates  (15). HAWIGER~ MARNEY, COLLEY,  AND  DES  PREZ  77 
The concept emerging from this work may be formulated as follows: Native 
IgG molecules do not interact with platelets, do not activate complement, and 
do not cause platelet injury manifested by amine release  (Fig. 9, panel at left). 
SPA in  optimal  concentration  forms complexes  with  IgG which  are able to 
interact  with  platelets  and  fix complement,  leading  to 5HT release  (Fig.  9, 
middle panel).  When higher  concentrations of SPA saturate the Fc fragment 
and  prevent  it  from  interacting  with  platelets  and  fixing  complement,  no 
release  reaction is observed (Fig.  9, right panel). 
The mode of activation of complement by SPA-sensitized  platelets is  still 
unknown. One may infer, from analysis of the profiles of consumption of single 
complement components by SPA-IgG complexes  (18), that the classical path- 
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CONCENTRATION  OF  IgG 
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IgG MODIFIED  ~  ACTIVATED COMPLEMENT 
BY SPA 
FIG. 9. A proposed concept of the complement-mediated platelet injury by the staphylo- 
coccal protein A. 
way of complement fixation  through C1 is involved. However, the possibility 
that complement is activated by SPA-sensitized  platelets through the alternate 
pathway  involving  C3  activator  (30) must  be considered.  Zimmerman  and 
Mttller-Eberhard have demonstrated that staphylococcal protein A accelerated 
coagulation in normal rabbit blood through a complement-mediated pathway, 
and  they postulated  that  both  pathways  of complement  activation  can  be 
involved (31). Our findings suggest that acceleration of blood clotting by SPA 
described by Zimmerman and Mttller-Eberhard  may be explained  by comple- 
ment-mediated platelet injury resulting  in activation of thromboplastic factors 
(e.g.,  platelet factor 3)  in  a  manner  analogous  to the effect of endotoxin on 
platelets (32). 
Complement-mediated platelet damage by SPA is a newly recognized biologic 
property  of  this  common  component  of  the  cell  wall  of  coagulase-positive 
staphylococci. Since platelet injury and amine release  play a role in vascular 
injury  (14)  and  since  complement-dependent  factors  chemotactic  for  poly- 
morphonuclear  leukocytes are  also  generated  by SPA  (33),  the phenomenon 
described  herein  may  contribute  to  the  development  of  inflammatory  and 
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SUMMARY 
A  new example of complement-mediated platelet  injury has been described. 
Staphylococcal protein A  (SPA) causes rabbit platelet injury as manifested by 
release  of platelet  5-hydroxytryptamine  (SHT).  This  reaction  is  complement- 
dependent  and  occurs  over  a  very  small  range  of  SPA  concentration,  larger 
amounts  being  inhibitory.  Complement  fixation  by  SPA  demonstrates  the 
same narrow  SPA concentration requirement  whereas precipitation  of IgG by 
SPA is roughly proportional  to  SPA concentration  over  a  wide concentration 
range.  The reaction  can be  separated  into  a  sensitization  step  which requires 
SPA  and  plasma  but not complement,  and  a  release  step  which does require 
complement. 
Complement-mediated  platelet  damage  induced  by  SPA  is  a  new  biologic 
property of this common component of the cell wall of pathogenic staphylococci 
which may contribute to the development of inflammatory and thromboembolic 
reactions  complicating  intravascular  staphylococcal  infection. 
We wish to thank Mrs. Aleksandra Hawiger/or expert assistance. 
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